Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Thioridazine hydrochloride
Drug ID BADD_D02201
Description A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Indications and Usage For the treatment of schizophrenia and generalized anxiety disorder.
Marketing Status approved; withdrawn
ATC Code N05AC02
DrugBank ID DB00679
KEGG ID D00798
MeSH ID D013881
PubChem ID 66062
TTD Drug ID D0U1OE
NDC Product Code 51079-566; 51079-567; 0378-0612; 46204-0006; 53489-500; 0378-0614; 51927-1928; 53489-148; 53489-150; 61876-0075; 0378-0618; 51079-565; 53489-149; 0378-0616; 51079-580
UNII 4WCI67NK8M
Synonyms Thioridazine | Thioridazine Hydrochloride | Thioridazine HCL | Thioridazine-Neurazpharm | Thioridazine Neurazpharm | ThioridazineNeurazpharm | Thiozine | Aldazine | Meleril | Mellaril | Melleril | Melleryl | Melleretten | Melzine | Rideril | Sonapax | Apo-Thioridazine | Apo Thioridazine | ApoThioridazine
Chemical Information
Molecular Formula C21H27ClN2S2
CAS Registry Number 130-61-0
SMILES CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001---
Agitation17.02.05.012; 19.06.02.001--
Agranulocytosis01.02.03.001---
Akathisia17.01.02.002; 19.06.02.006--
Akinesia17.01.02.003---
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaemia01.03.02.001--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Aplastic anaemia01.03.03.002---
Asthma10.01.03.010; 22.03.01.002---
Autonomic nervous system imbalance08.01.01.010; 17.05.01.011; 24.06.01.005---
Breast engorgement18.08.02.001; 21.05.05.002---
Cholestasis09.01.01.001---
Confusional state17.02.03.005; 19.13.01.001--
Constipation07.02.02.001--
Corneal pigmentation06.06.03.013---
Dermatitis23.03.04.002---
Dermatitis contact10.01.01.003; 12.03.01.040; 23.03.04.004---
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Dry mouth07.06.01.002--
Dyspnoea02.11.05.003; 22.02.01.004--
Ejaculation failure21.03.01.003---
Electrocardiogram QT prolonged13.14.05.004--
Electrocardiogram T wave inversion13.14.05.007---
Eosinophilia01.02.04.001--
Erythema23.03.06.001---
Extrapyramidal disorder17.01.02.007--
Galactorrhoea05.03.04.002; 21.05.02.002---
Gynaecomastia05.05.02.003; 21.05.04.003--
The 1th Page    1 2 3    Next   Last    Total 3 Pages